Kurosaki Hajime

Affiliation and department：

Research field (1)： Tumor biology

Research theme for competitive and other funds (6)：

2020 - 2023 Development of oncolytic vaccinia virus with enhanced remote infection capability for ovarian cancer
2016 - 2020 新規人工染色体ベクターを用いた血友病に対する細胞補充療法の開発
2014 - 2016 新規人工染色体ベクターを用いた血友病に対する再生補充療法の開発
2012 - 2014 ゲノム補完人工染色体を用いた血友病遺伝子治療モデルの検討
2009 - 2012 血友病治療のためのヒト人工染色体の開発

Show all

Papers (15)：

Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, Nozomi Kuwano, Masato Yamane, Kenta Ishii, Yoshiyuki Fujiwara, Takafumi Nakamura. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Cells. 2021. 10. 5
Motomu Nakatake, Nozomi Kuwano, Emi Kaitsurumaru, Hajime Kurosaki, Takafumi Nakamura. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment. Molecular Therapy. 2020
Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, Midori Yamashita, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Science translational medicine. 2020. 12. 526
Motomu Nakatake, Hajime Kurosaki, Nozomi Kuwano, Kosuke Horita, Mai Ito, Hiromichi Kono, Tomotaka Okamura, Kosei Hasegawa, Yasuhiro Yasutomi, Takafumi Nakamura. Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function. Molecular therapy oncolytics. 2019. 14. 159-171
Horita K, Kurosaki H, Nakatake M, Ito M, Kono H, Nakamura T. Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochemical and biophysical research communications. 2019. 516. 3. 831-838

ｍore...

MISC (7)：

Motomu Nakatake, Hajime Kurosaki, Kosuke Horita, Nozomi Kuwano, Kenta Ishii, Miyuki Nomura, Teruhisa Sakamoto, Tomotaka Okamura, Yasuhiro Yasutomi, Takafumi Nakamura. Preclinical Study of Tumor-Targeted and Armed Oncolytic Vaccinia Virus for Systemic Cancer Virotherapy. MOLECULAR THERAPY. 2017. 25. 5. 59-59
N. Uno, K. Ueda, Y. Iida, Y. Yakura, H. Kurosaki, K. Uno, M. Osaki, T. Obayashi, Y. Kazuki, M. Hiratsuka, et al. Toward safe and effective gene- and cell-therapies using human artificial chromosomes and stem cells. CHROMOSOME RESEARCH. 2015. 23. 2. 368-368
Ikumi Goto, Naoyoshi Nitta, Motomu Nakatake, Nao Okada, Masato Yamane, Hajime Kurosaki, Takafumi Nakamura. Deletions of Both Vaccinia Growth Factor and O1 Protein Genes Enhance Therapeutic Index of Oncolytic Vaccinia Virus. MOLECULAR THERAPY. 2014. 22. S67-S68
矢倉裕奈, 石原千恵, 藤井昂洸, 香月康宏, 黒崎創, 土井健史, 小松則夫, 押村光雄, 武谷浩之. ヒト人工染色体とiPS細胞を用いた新規血友病遺伝子治療法. 生化学. 2011. ROMBUNNO.2T15P-16
黒崎創, 平塚正治, 香月康宏, 今岡奈津子, 石原知恵, 宇野愛海, 武谷浩之, 押村光雄. 血友病A型細胞補充療法を目指したヒト第VIII因子発現HACベクターの有用性の検討. 再生医療. 2010. 9

ｍore...

Patents (3)：

Lectures and oral presentations (2)：

Preclinical toxicological evaluation in cynomolgus monkey with tumor-targeted and armed oncolytic vaccinia virus purified through manufacturing process
(2018)
Preclinical toxicological evaluation of tumor-targeted and armed oncolytic vaccinia virus in cynomolgus monkey
(第23回日本遺伝子細胞治療学会 2017)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page